Healthcare
Live Price
Offline$4.54
+6.82% today
1Y Change
-34.86%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Exagen Inc. (XGN) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $4.54 and down 34.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +19.7%, EPS growth of -12.0%, a dividend yield of 0.0%. What stands out right now is revenue +19.7%, EPS -12.0%, free cash flow -3.4% with operating margin -21.1% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XGN Max Drawdown
-77.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$48.3M
+6.0% YoY
FY Net Income
-$26.9M
+43.3% YoY
Free Cash Flow
-$22.6M
+37.9% YoY
Revenue Growth
+19.7%
EPS Growth
-12.0%
Gross Margin
58.3%
Net Margin
-30.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 67M | 56M | 53M | 46M | 48M |
| Gross Profit | 39M | 33M | 29M | 21M | 28M |
| Operating Income | -14M | -14M | -23M | -46M | -24M |
| EBITDA | -12M | -11M | -19M | -44M | -23M |
| Net Income | -20M | -15M | -24M | -47M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32M | 22M | 36M | 62M | 99M |
| Total Assets | 58M | 45M | 57M | 86M | 123M |
| Total Liabilities | 41M | 35M | 34M | 44M | 39M |
| Shareholder Equity | 17M | 10M | 23M | 42M | 85M |
| Total Debt | 5M | 23M | 23M | 35M | 28M |
| Net Debt | -27M | 969K | -13M | -27M | -71M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20M
+36.9% YoY
Capital Expenditures
2M
+45.1% YoY
Free Cash Flow
23M
+37.9% YoY
Key ratios
Gross Margin
58.3%
Operating Margin
-21.1%
Net Margin
-30.0%
ROE
-126.6%
Debt / Equity
1.59x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.